Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid
View Patent ↗Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
1. An atorvastatin morpholine having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK α radiation: 9.7, 16.0, 18.9, 19.6, 20.8, 22.1, 23.9, and 25.0, or a solid state 19 F nuclear magnetic resonance having the following chemical shifts expressed in parts per million: −117.6.
2. An atorvastatin morpholine having an x-ray powder diffraction pattern containing the following 2 θ peaks measured using CuK α radiation: 4.8, 5.7, 6.4, 8.6, 9.7, 12.8, 14.1, 14.6, 16.0, 16.3, 16.5, 17.3, 17.5, 18.1, 18.9, 19.2, 19.6, 19.9, 20.8, 21.2, 22.1, 23.1, 23.9, 24.6, 25.0, 25.7, 27.0, 28.1, 28.5, 29.6, 30.1, 30.9, 31.0, 32.9, 32.4, 33.4, 33.9, 34.6, 35.4, 36.8, and 37.6.
3. An atorvastatin morpholine characterized by solid state 13 C nuclear magnetic resonance having the following chemical shifts expressed in parts per million:
179. 3, 165.9, 162.7, 160.5, 139.6, 137.8, 134.3, 131.2, 129.6, 128.7, 127.4, 122.9, 120.8, 117.9, 116.3, 70.8, 69.5, 63.4, 42.4, 41.2, 40.5, 24.8, and 20.6.
4. An atorvastatin morpholine characterized by solid state 13 C nuclear magnetic resonance having the following chemical shifts expressed in parts per million:
179. 3, 165.9, 160.5, 24.8, and 20.6.